Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 33153635.
- Also identified by DOI 10.1016/j.mayocp.2020.08.030 and PMC identifier 7458092.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A higher risk of thrombosis has been described as a prominent feature of coronavirus disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis risk, prognostic implications, and anticoagulation effects in COVID-19. We included 37 studies from 4070 unique citations. Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were frequent among patients with COVID-19 and further increased in those with more severe forms of the disease. We also present guidance on the prevention and management of thrombosis from a multidisciplinary panel of specialists from Mayo Clinic. The current certainty of evidence is generally very low and continues to evolve.
Medical subject headings
- Anticoagulants
- Practice Guidelines as Topic
- SARS-CoV-2
- Thrombosis
- COVID-19 Drug Treatment